Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026)
Ani Pharmaceuticals (ANIP) reported Income from Continuing Operations of 29492000.0 for Q1 2026, up 88.0% on a YoY basis from 15687000.0 in Q1 2025, and up 7.15% sequentially from 27525000.0 in Q4 2025.
Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 16 years of Income from Continuing Operations data on file, last reported at 29492000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 88.0% year-over-year to 29492000.0; the trailing twelve-month figure through Mar 2026 stood at 92159000.0 (up 537.39% YoY), and the FY2025 full-year result was 78337000.0, up 522.94% from the prior year.
- Income from Continuing Operations climbed to 29492000.0 in Q1 2026, from 27525000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 29492000.0 in Q1 2026 to a low of 24198000.0 in Q3 2024.
- A 5-year average of 3541470.59 and a median of 1465000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 23472.09% in 2022 and soared 1144.71% in 2024, its largest moves.
- Tracing ANIP's Income from Continuing Operations over 5 years: stood at 4280000.0 in 2022, then jumped by 126.96% to 1154000.0 in 2023, then slumped by 990.12% to 10272000.0 in 2024, then surged by 367.96% to 27525000.0 in 2025, then rose by 7.15% to 29492000.0 in 2026.
- Business Quant data shows ANIP's Income from Continuing Operations at 29492000.0 in Q1 2026, 27525000.0 in Q4 2025, and 26617000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 29.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.49 Mn |
| Dec 31, 2025 | 27.53 Mn |
| Sep 30, 2025 | 26.62 Mn |
| Jun 30, 2025 | 8.53 Mn |
| Mar 31, 2025 | 15.69 Mn |
| Dec 31, 2024 | -10.27 Mn |
| Sep 30, 2024 | -24.20 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Mar 31, 2024 | 18.24 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 9.91 Mn |
| Jun 30, 2023 | 6.25 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | -4.28 Mn |
| Sep 30, 2022 | -8.60 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | -20.10 Mn |
| Dec 31, 2021 | -24.14 Mn |
| Sep 30, 2021 | -4.42 Mn |
| Jun 30, 2021 | -14.16 Mn |